RA Capital Management 13F holdings, Q4 2010
Holdings as of December 31, 2010 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 16 US equity positions worth $101.1m in its Q4 2010 13F filing. The largest position was ARTHROCARE CORP at 11.3% of the reported book, followed by DYNAVAX TECHNOLOGIES CORP and SEQUENOM INC. Against the Q3 2010 filing, it opened 8 new positions, added to 2 and reduced 6 among the top 16 holdings.
What did RA Capital Management own in Q4 2010? Top 16 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2010 |
|---|---|---|---|---|---|---|---|
| 1 | ARTHROCARE CORP | 11.3% | $11.4m | 368,630 | -1% | reduced | |
| 2 | DYNAVAX TECHNOLOGIES CORP | 10.5% | $10.6m | 3,325,000 | – | new | |
| 3 | SEQUENOM INC | 10.4% | $10.5m | 1,304,850 | 273% | added | |
| 4 | JAZZ PHARMACEUTICALS INC | 8.3% | $8.3m | 424,040 | -45% | reduced | |
| 5 | ALXN ALEXION PHARMACEUTICALS INC | 8.1% | $8.1m | 101,050 | -33% | reduced | |
| 6 | PHARMASSET INC | 8.0% | $8.1m | 185,261 | -35% | reduced | |
| 7 | BSTC BIOSPECIFICS TECHNOLOGIES CO | 7.6% | $7.7m | 300,000 | -52% | reduced | |
| 8 | ONYX PHARMACEUTICALS INC | 7.4% | $7.5m | 202,050 | – | new | |
| 9 | BIIB BIOGEN IDEC INC | Healthcare | 7.0% | $7.1m | 106,030 | – | new |
| 10 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 6.4% | $6.5m | 103,050 | 4% | added |
| 11 | VALEANT PHARMACEUTICALS INTL | 5.9% | $6.0m | 211,500 | – | new | |
| 12 | EXK EXACT SCIENCES CORP | Basic Materials | 4.2% | $4.2m | 709,920 | – | new |
| 13 | COLUMBIA LABS INC | 2.3% | $2.3m | 1,020,343 | – | new | |
| 14 | XENOPORT INC | 2.2% | $2.3m | 265,000 | – | new | |
| 15 | CORT CORCEPT THERAPEUTICS INC | Healthcare | 0.3% | $270.0k | 70,000 | – | new |
| 16 | VISION-SCIENCES INC DEL | 0.1% | $142.0k | 102,298 | -59% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.